This Panel Reads Your Skin Tone, Then Gives You Five Minutes of Sun

Sunlight has a supply problem. Get too little and vitamin D levels fall, along with a range of other biological processes tied to UVB exposure. Get too much and you're accumulating skin damage. And the dose is almost impossible to control — it shifts with the season, the weather, the time of day, your latitude, and your skin tone.

Solius is an attempt to take that variable out of the equation entirely.

The UVB light therapy device, made by Solius Labs in Bainbridge Island, Washington, is the first UVB panel the FDA has cleared for over-the-counter use without a prescription. It scans your skin, calculates a dose specific to you, and delivers roughly five minutes of light once a week.

The Problem With Getting Sun From the Sun

Natural sunlight delivers UVB — the wavelength that triggers vitamin D production in skin — bundled together with UVA, which contributes little to that process and a great deal to premature aging and DNA damage. You can't take one without the other.

That's the fundamental inefficiency. To get a meaningful UVB dose from the sun, you have to absorb a large amount of UVA alongside it. And because the ratio changes constantly with conditions, nobody can actually tell you how much they got.

Supplements sidestep the sun but don't fully replace it. Solius points to something the research has been circling for years: population studies consistently link higher sun exposure to lower mortality, but vitamin D supplementation trials haven't reproduced that benefit. The implication is that vitamin D is a marker of sun exposure rather than the whole mechanism — that UVB is doing other things in the body, through pathways a pill doesn't touch.

That gap is the space Solius is built for.

What the Device Actually Does

Solius uses medical-grade UVB LEDs tuned to approximately 293 nanometers — deliberately close to the 295–297 nm range where research shows vitamin D production is most efficient. It isolates that narrow slice and largely eliminates the UVA that comes with sunlight.

The precision has a measurable consequence. Across the full UV spectrum, Solius says it delivers roughly 99% less total UV radiation than natural sunlight for an equivalent benefit. The company's framing: a full year of weekly sessions carries less UV exposure than five minutes of afternoon sun.

The personalization is the harder engineering problem. A dose that's right for very fair skin is inadequate for darker skin, and vice versa — melanin absorbs UV, meaning identical exposure produces different biological results in different people. Solius uses a patent-pending, FDA-cleared skin sensor that analyzes the user's skin and calibrates the dose accordingly, adjusting over time based on how the skin responds.

Around that sits a set of safeguards that reveal what the company is worried about: distance sensing to confirm correct positioning, AI-assisted eyewear detection to check protective glasses are actually on, and an enforced 24-hour lockout between sessions to prevent anyone from overusing it. Each user gets their own profile in the app.

What the Clinical Evidence Shows — and What It Doesn't

This is where precision matters.

Independent research from Boston University, published in Anticancer Research, found Solius produced a 10.2 ng/mL increase in serum vitamin D, with participants showing a mean individual increase of 76% from baseline.

That's the claim the FDA clearance covers. Solius is cleared as a Class II medical device intended to stimulate vitamin D production in people 22 and older — nothing broader. The company states plainly that the device is not intended to diagnose, treat, cure, or prevent disease.

The wider claims on the site — bone density, mood, cardiovascular function, gut microbiome, muscle repair — are drawn from published research on UVB and sunlight generally, not from trials of this device. Solius is careful to attribute them that way, linking to the underlying studies. That distinction is worth holding onto: the mechanism is plausible and the literature is real, but "UVB exposure is associated with X in population studies" is a different statement from "this device produces X."

How It Differs From Devices People Already Know

The comparison most people reach for is a tanning bed, and it's the wrong one. Tanning beds emit predominantly UVA — often 95% or more — which is precisely the wavelength Solius is designed to exclude. They produce tanning and aging with negligible UVB benefit.

SAD lamps and red-light panels are also a different category entirely. They use visible light, not UVB, and don't activate the same biological pathways.

The closest relative is narrowband UVB phototherapy, the clinical technology dermatologists have used for decades to treat psoriasis, eczema, and vitiligo. Those systems use bulb technology developed in the 1980s, peaking around 311–313 nm, with meaningful secondary emissions outside the target range — including UVA. Solius sits closer to the biological sweet spot for vitamin D, and adds the dosing and safety layer that clinical phototherapy machines don't have, because in a clinic a trained operator provides it.

That's the actual innovation here. Not the light — UV phototherapy won a Nobel Prize in 1903. The innovation is building enough automated safety and personalization around it that the FDA was willing to let people use it at home, unsupervised.